



# Aktiespararna – Stora Aktiedagen Stockholm

F.R. Martelet, M.D., CEO

2 December 2021

---

# Forward-looking statement



## Important notice

The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require preparation of further prospectuses or other offer documentation, or be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

No representation or warranty expressed or implied is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinion contained herein.

The information in this presentation may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

## Forward looking statements

This presentation contains forward-looking statements that reflect management's current views with respect to certain future events and potential financial performance. Although Oasmia believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of various factors.

Important factors that may cause such a difference for Oasmia include but are not limited to: (i) the macroeconomic development, (ii) change in the competitive climate and (iii) change in interest rate level.

This presentation does not imply that Oasmia has undertaken to revise these forward-looking statements, beyond what is required by applicable law or applicable stock exchange regulations if and when circumstances arise that will lead to changes compared to the date when these statements were provided.

Our vision

**Creating a Nordic oncology  
powerhouse focused on  
hard-to-treat cancers**

## Our mission

**To build a diversified pipeline  
focused on hard-to-treat  
and late-stage cancers using  
different mechanisms of action**

# Transforming Oasmia since March 2020



**Rightsizing  
the company**  
and terminating  
commercial drug  
production



**Putting our  
finances in order**  
by eliminating  
unnecessary  
operating  
expenditure



**Building  
the in-house  
capabilities**  
to make us an  
attractive partner  
for innovative assets  
and companies



**Reducing  
business risks,**  
including resolving  
inherited legal issues



# Positioned for the next phase of execution



## Transformation journey




### New strategy & focus

Development of internal and in-licensed products  
Revenues from out-licensed products and technologies

## Building a Nordic oncology powerhouse

### Delivery of String-of-Pearls strategy

- M&A and in-licensing to create oncology development engine
- Multiple shots on goal with broader MoA targeting range of tumor types
- Expanded investor base including international specialist institutions



# Our current areas of focus

## Oncology R&D

in-licensed & wholly-owned  
development-stage assets:

- Cantrixil
- Docetaxel micellar
- Strategic pipeline development



## Commercial

revenues from out-licensed  
products and technologies:

- Apealea® for ovarian cancer
- XR-17™/ XR-18 drug delivery technologies
- Animal health assets for partnering




# Recent achievements and milestones

- Building our capabilities – experienced Heads of Clinical Development & Regulatory Affairs appointed
- Maximizing Apealea
  - License agreement with FarmaMondo in Russia & CIS
  - Inceptua planning to launch in selected countries (Germany, UK) in 2022 as a first step of commercialisation in Europe
  - Elevar reviewing best clinical & regulatory pathway for Apealea in the US
- Driving our pipeline of therapies for hard-to-treat cancers
  - Cantrixil Phase 2 preparations continuing with first scientific advisory board (SAB) meeting and manufacturing supply in negotiation
  - Docetaxel micellar Phase 1 study enrolment on track to be completed late 2022 with 3 Swiss centers opened
  - Karolinska Institutet research into XR-17 making good progress
- Business development and licensing progress during the quarter
  - Accelerating focus on in-licensing and M&A working with investment banks
- Reducing business risks – global settlement of inherited legal disputes announced post-period end



# Comprehensive in-house capabilities in place



# A new team to deliver success



## Capabilities and experience to build a diversified oncology pipeline


Business Development	Partnering	Pipeline	Regulatory	Clinical	Product Development	
<p><b>Francois Martelet, MD</b> Chief Executive Officer</p>	<p><b>Fredrik Järsten</b> Chief Financial Officer</p>	<p><b>Dr Heidi B Ramstad</b> Chief Medical Officer</p>	<p><b>Reinhard Koenig, MD</b> Chief Scientific Officer</p>	<p><b>Peter Selin, BSc</b> Chief Business Officer</p>	<p><b>Kia Bengtsson</b> Head of Clinical Development</p>	<p><b>Johanna Röstin</b> Head of Regulatory Affairs</p>

# The 'string of pearls' approach to build critical mass

Leveraging our development, regulatory & commercial partnering skills

Evaluating a wide range of targets with multiple mechanisms of action (pre-clinical to late Phase 3)

Potential for high value exit opportunities from Phase 2



# Cantrixil – the first of our string of pearls

- Global rights to first-in-class Cantrixil licensed from Kazia Therapeutics Limited (ASX:KZA) March 2021
- Targeting ovarian cancer – an area of unmet need with 314k new cases and 207k deaths worldwide in 2020\*
- Tubulin-binding small molecule with potent cytotoxicity against CD 44+ ovarian cancer stem cells, ovarian somatic cancer cells (CD 44+), both resistant to standard chemotherapies
  - Potential to improve outcome in relapsed ovarian cancer
  - Favorable safety and PK profiles in I.P. use
- Orphan drug designation from US FDA
- Strong patent protection to 2035

## Next steps

- Clinical Advisory Board set up and meeting convened
- Initiation of interactions with FDA & EMA to validate Phase 2 trial design
- Securing study drug supply

# Docetaxel micellar – Phase 1b in prostate cancer underway

## Phase 1b trial initiated by SAKK – Swiss Group for Clinical Cancer Research

- Open-label, multicenter, single-stage trial at major hospitals in Switzerland
- Recruiting 18 chemotherapy-naïve patients with metastatic castration resistant prostate cancer (mCRPC) with adequate bone marrow, liver and renal function

## Docetaxel approved for wide range of solid malignancies


- Standard of care for advanced prostate cancer
- Docetaxel micellar uses XR-17™ to enable IV administration of docetaxel without solubility enhancers

## The global burden of prostate cancer



# 5<sup>th</sup>

Leading cause of death in men worldwide in 2018



# 1.28m ↗

Cases are predicted to almost **double** by 2040

# Research with Karolinska Institutet



- Evaluation of the biological interactions of XR-17 platform with cellular systems in-vitro
- Objective to expand our understanding of XR-17 and evaluate future applications for active pharmaceutical ingredients (APIs)
- Research began in H1 2021 on cellular mechanisms and is nearing completion




**Karolinska  
Institutet**

# Apealea<sup>®</sup> – providing future milestones & royalties




Worldwide commercial agreement with Elevar & its partners



Global agreement with US-based Elevar Therapeutics, a subsidiary of South Korea's HLB, worth up to \$698m + royalties (incl. \$20m upfront)

# The growing market for targeted cancer therapies


The global cancer immunotherapy market size was valued at **\$85,603.50m in 2020\*** and is projected to reach **\$309,667.9m by 2030**, registering a **CAGR of 14.1%** from 2021 to 2030.





# Adding new oncology programmes with cutting edge science

Multiple shots at goal with new state of the art mechanisms of action:



Small molecules



Solubilization technologies (XR-17™/XR-18)




Antibodies



Oncolytic viruses



Gene therapies



CAR-T therapies



Antibody drug conjugates (ADCs)



Cell therapies

# Applying Oasmia's proven strengths to create value & diversify risk



# Focus on hard-to-treat cancers


Product	Indication	Pre-clinical	Phase 1	Phase 2	Phase 3	Registration / approval	Commercial Launch	Geography
Cantrixil IP	Ovarian cancer	→						Global
Docetaxel micellar	Prostate cancer	→						EU/EAA
Cantrixil IV	Ovarian cancer	→						Global



# Q3 financial results demonstrate careful cash management

- Net sales of MSEK 11.9
  - Drug products shipped to Elevar
- Operating costs totalled MSEK 26.4
  - Further reduction since Q2, implying annualized cost savings of more than MSEK 100
- Operating loss of MSEK -29.6
- Operating cashflow of MSEK -26.8
  - Reduced "cash burn" in Q3 to approx. MSEK 9 per month
- Cash and cash equivalents amounted to MSEK 150 at the end of the quarter

## Significant reduction in Opex (MSEK)



# Oasmia and sustainability

- Global settlement announced post-period end addresses all disputes with MGC Capital, former Board Members of Oasmia and members of former management
  - Settlement will result in a negative cashflow effect of MSEK 24.5 but with a positive earnings effect of MSEK 32.5 in the fourth quarter of 2021

**ESG aspects have been identified through an internal materiality assessment, and confirmed in **dialogue** with our key stakeholders:**



Good governance within our company, and in relation to our stakeholders



Attract and retain the right talent for efficient product development



Strong business ethics in everything we do



Offer a safe and supportive work environment



Minimize our environmental footprint



Be a responsible customer and expect the same from our supply chain

Structure to support Oasmia's sustainability work:

The Board is responsible for ensuring that sustainability is adequately addressed within the Company. The CEO is responsible for implementation. All employees are responsible for supporting ongoing sustainability initiatives in their daily work.

Policies and instructions adopted, for example:

- Code of Conduct
- Whistle-blower policy
- Employee handbook
- Detailed plans and instructions

# Building a global oncology business – multiple catalysts to drive value in 2022

## Potential near- and mid-term value drivers

- Sustained M&A & in-licensing to build critical mass in oncology
- Cantrixil – preparation for Phase 2 initiation
- Docetaxel micellar – Phase 1b completion of enrolment
- XR-17™ technology platform – enhancement through Karolinska program
- Apealea® – further partnering by Elevar; potential for initial revenues from royalties and milestones
- Animal Health assets – divestment or partnering agreements

# Summary

**Opportunity to create a Nordic oncology powerhouse focused on hard-to-treat cancers**



**Capabilities and experience in place** to build a diversified oncology pipeline



**String of pearls strategy** to build critical mass



**Multiple shots on goal** through diversified mechanisms of action targeting varied tumor types




**A strong platform** for innovative partners & high potential assets



Positioned to attract **international institutional specialist investors**





Thank you

**oasmia**

**Oasmia Pharmaceutical AB (STO: OASM)**  
Vallongatan 1  
752 28 Uppsala  
Sweden



+46 018-50 54 40



[IR@oasmia.com](mailto:IR@oasmia.com)



[www.oasmia.com](http://www.oasmia.com)



[www.linkedin.com/company/oasmia-pharmaceutical-ab](http://www.linkedin.com/company/oasmia-pharmaceutical-ab)



[www.twitter.com/Oasmia](http://www.twitter.com/Oasmia)